Burgundy - Bourgogne Développement

Comments

Transcription

Burgundy - Bourgogne Développement
HEALTHCARE
Bioscan (Dijon)
Staf Van Cauter
President and CEO
Oncodesign Biotechnology (Dijon)
Philippe Genne
CEO
“Bioscan is very excited to launch our new subsidiary
in the Burgundy region.
The high quality of the local talent pool, the presence
of institutional partners via the Pharm’Image consortium, and the strong support of both national, regional and local public authorities under coordination
of the Burgundy Development Agency, give us great
confidence in our future plans for BMIF.”
“Oncodesign Biotechnology is a leading company
in preclinical research of anticancer therapies and has over
400 pharma laboratories customers worldwide. With such
background and the commitment to be at the cutting edge
of drug discovery in oncology, Oncodesign Biotechnology
has created in 2005 the Pharm’image cluster which combines
private and public partners to develop translational research
within innovative in vivo imaging platforms. Located in Dijon
and unique in France, Pharm’image gathers a wide spectrum
of competences with several biotech., the University Hospital,
academic laboratories of the University of Burgundy and the
CGFL, an anticancer research centre.”
compagnies
5000
employees,
scientists,
engineers,
technicians
1000
PhDs per year
within 6 doctoral
schools of the
University of
Burgundy
Sanofi Aventis (Quetigny)
Alain Louvel
Managing Director of the
production plant
2000
INSERM Research Centre
“Lipid, Nutrition and Oncology” (Dijon)
Dr Carmen Garrido
Research Director of the unit
“Stress proteins and Oncology”
“Historically, Dijon has always been a wellknown
pharmaceutical area in France. With more than 40
years experience, our drug production plant located
in the suburbs of Dijon gathers 450 employees and
produces a wide range of drugs from which 60% is
exported worldwide over 95 different markets.”
beds capacity
in the University
Hospital
“Burgundy-Dijon has a geographical key-position in France
for managing scientific collaborations. We get by TGV
(high-speed train) to Paris only in 1h40, CDG International
Airport or in Lausanne in 2h and Marseille in 3h. I can
easily and quickly connect all my research partners or
attend scientific congresses in France, Europe or in NorthAmerica. It boosts the attractiveness of my scientific unit
to develop academiccollaborations worldwide at the
cutting-edge of drug discovery in oncology.”
600
employees
are managed
by the French
Great Eastern
Cancer Clinical
Research Centre
(headquarter
located in Dijon)
Urgo Laboratories
(Chevigny-St-Sauveur)
Etienne Bayle
Supply Chain Manager
CGFL Anticancer center
University hosptial center
“Since the establishment of our company in 1890,
the geographical position of the region Burgundy
and Dijon, its main city, has always been a key-success factor for developping our markets. Nowadays,
we deliver our products to more than 90% of our customers within 24h transportation by trucks from our
new building in the suburbs of Dijon.”
Ferdinand Cabanne biobank
ICMUB
Inserm
LE2I
Frankfurt
Novarea
Technological park
Beaune
LICB
Oncodesign Biotechnology
Pharm'image cluster
Premice incubator
University of Burgundy
Welience transfert center
Burgundy,
Business First
Basel
Geneva
Lyon
Milano
Lausanne
Burgundy Development Agency
Phone : +33 380 285 566
[email protected]
Paris
DIJON
Health
care Edition Octobre 2013 - Crédit photo Shutterstock
100
Brochure cofinancée par l’Union Européenne.
L’Europe s’engage en Bourgogne avec le Fonds
européen de développement régional.
www.investburgundy.com
www.burgundy-healthcare.com
UNITED KINGDOM
Medical
London
Life Science
Technologies
Paris
BELGIUM
Arc Sur Tille
LARS
Brussels
Auxerre
Agencinox
Biotechnologies
Orléans
Auxerre
A7 7
Nantes
LUXEMBOURG
A5
Champs-Sur-Yonne
A6
Champs-sur-Yonne
TechMed
Digoin
Laboratoires Coluxia
Arc sur tille
Pouilly-en-Auxois
Corbigny
Frankfurt
GERMANY
Auxonne
Meursault
Gevrey-Chambertin
Chalon-sur-Saône
St Vincent en Bresse
Le Creusot
Montceau
Simandre
A6
Digoin
La Roche Vineuse
Mâcon
Nantes
Bordeaux
Freiburg
Basel
SWITZERLAND
A39
Nevers
Chalon-sur-Sâone
Dynamic 3D
Fovea Interactive
Holiste
Dijon
Lausanne
Geneva
Pharma /Cosmetics
Dijon
Bioact
CEN Biotech
CEN Nutriment
Chematech
Cohiro
ICTA
ICMUB
INSERM
Inventiva
Lara-Spiral SA
LICB
Naxagoras Technology
Nexidia
NVH Medicinal
Oncodesign Biotechnology
Pharm’image cluster
Premice incubator
University hospital center
University of Burgundy
Vitagora cluster
Vivexia Laboratory
Welience transfert center
Auxonne
Global Hygiène
Sens
Chemical
Dijon
Arplay Medical
Bioscan
CCITI
CLM Industrie
Crossject
EyeNetics
Global Hygiène
Laboratoires Urgo
ODIL SAS
Plasto Pharma
Plasto Technology
Proteor
Oslo
Stockholm
Pouilly en Auxois
IDS France SA
Nevers
Centrepharma
Cephalon
OCP Répartition
Berlin
Milano
ITALY
Research institut, university, hospital
centre, technology transfer centre,
cluster, incubator, startup and biotech
dedicated to foster R&D to develop
innovative drugs and medical device
(drug discovery, CRO preclinical &
clinical research, technological and
analytical platform, drug delivery
technologies, etc.)
Pharma, healthcare companies,
CDMO’s and other comprehensive service providers (process
technologies, analytical, quality
control, formulation and analytical development, regulatory,
marketing, sale force, packaging, logistics, etc.)
Paris
1h30
2h
Medical device, diagnostic manufacturer and
service provider (IT, imaging, orthopaedic, dressing, wound plasters,
hygiene and medical
packaging, regulatory,
marketing, sale force,
logistics, etc.)
Amsterdam
Lille
Nantes
Chemical
Pharma / Cosmetics
Bordeaux
Brussels
Frankfurt
Strasbourg
Dijon
Sens
TEVA Santé
Prague
München
Basel
Geneva
Lyon
Milano
Toulouse
Madrid
Le Creusot - Montceau
Brenntag
Meursault
Spa Bourgogne Cosmétiques
London
Life Science
Biotechnologies
Dijon
Alliance Healthcare
CERP
Cordem Pharma
Demosthène
FILAB
GLATT Pharmatech
Laboratoires Boiron
Laboratoires Urgo
Laboratoires Vendôme
Merck Médication Familiale
Sanofi
Serayet-Wyld
SPPH-Fareva
OCP Répartition
Recipharm Fontaine SAS
Mâcon
Laboratoires Gabriel Couzian
Lyon
Medical
Technologies
Corbigny
Pharma Développement
La Roche Vineuse
Lab-Service SA
Le Creusot - Montceau
BSE
Capron Podologie
Eolane
Vitaris France
SPAIN
Chalon Sur Sâone
CERP
MRI Technologies
Gevrey-Chambertin
Laboratoires Juva Santé
Sens
GeR
Barcelona
Auxerre
Laboratoires Macors
Roma
Saint Vincent en Bresse
Cellande SA
Simandre
Rexam
Burgundy Development Agency
Presentation
Founded in 2005 by the Regional Council of Burgundy, Burgundy Development Agency aim at improving the attractiveness
of Burgundy for Foreign Direct Investments (FDI). It’s funded by the Regional Council of Burgundy, four District councils &
main Towns of Burgundy, Chamber of Commerce, Companies and Regional banks.
Services are tailor-made, confidential and free of charge to help companies set up their business in Burgundy (creation,
expansion, merger & acquisition, partnerships, etc.).
For 15 years we’ve been helping about 200 companies to successfully set up and develop their businesses in Burgundy.
Main sector
•
•
•
•
Chemical/Pharma/Cosmetics
Nutrition/Healthcare
Medical technologies
Life Science Biotechnologies
Subsector
• Healthcare functional foods, nutraceutical products manufacturers (SPPH, Merck MF, Urgo, etc.)
• Pharma & cosmetics CMO’s, CDO’s (SPPH, Centre Pharma, Macors, etc.)
• Pharma and biotechs. drug discovery and services, CRO’s, pharmaco-imaging cluster to improve drug development
especially in Oncology and Cardiology (GIE Pharm’Image, Oncodesign Biotechnology, ICTA, etc.)
• Transdermal drug delivery and medical tapes manufacturers (Plasto Pharma, Urgo, Coluxia)
• Prosthetics and orthotics components, systems and equipment’s for disabled people manufacturers (Proteor)
Primary therapeutic area(s) :
Oncology, Cardiology, Biomedical equipment for disabled people, Wound care products, OTC’s.
Partnering strategy / collaborations
Promoting clusters, universities, business networks and infrastructures to locate new investments within the brand
« Invest in Burgundy »,
Prospecting new investments projects of foreign companies & doing the follow-up of those already settled in Burgundy,
Managing the national and local public bodies to ease the regulation and funding process for new investments in Burgundy.
Client portfolio
Bioscan Molecular Imaging France., IDS France SA, Centre Pharma, Teva, Crossject, Pharma Développement.
Address
Burgundy Development Agency
Maison Régionale de l’Innovation - 64 A rue Sully - CS 77124 - FR - 21071 Dijon Cedex - France
Contact
Fouad Bounouidrate - Project manager Pharma/Biotech/Biomedical
Burgundy Development Agency - www.investburgundy.com Phone : +33 3.80.28.55.69 - Mobile : +33 6.78.38.27.48 - [email protected]
CGFL preclinical imaging platform
Presentation
The CGFL (Centre Georges François Leclerc) preclinical imaging platform is located in the heart of the regional anticancer
center in Dijon, and offers a full-range translational expertise from preclinical to clinical research.
Our lab enables a full approach of preclinical imaging from chemistry to in vivo evaluation (SPECT, PET, CT, MRI, planar
imaging) in a totally dedicated environment (authorized for radioactivity & animal handling). A wide-range of possible
experimental endpoints could be longitudinally assessed in the same animal using imaging (tissue perfusion, metabolism,
cardiac function, drug-targeting, PK/PD) resulting in cost and timeline reduction.
Local partnerships:
• Member of PharmImage® consortium, a public-private partnership focused on pharmaco-imaging
• Member of Engicare®, a grouped customized services offer focused on biomolecule development combining engineering/
biomanufacturing and biological validation capabilities
• Hosts IMAPPI project which develop a preclinical PET-MRI prototype with Bioscan.
Main sector
Biotechnology / R&D services – Preclinical imaging
Subsector
CRO / diagnostics services / drug delivery / screening
Primary therapeutic area(s) :
Neoplasms / cancer / oncology
Endocrine / nutritional and metabolic diseases
Cardiovascular
Partnering strategy / collaborations
Seeking new contacts with companies interested in our contract research services or partnering collaborations
Client portfolio
Biotech / Pharma industry
Address
CGFL – Nuclear Medicine department
1 rue Pr Marion – BP77980 – 21079 DIJON Cedex - FRANCE
Contact
Alexandra Oudot, PhD
[email protected] - +33 3 45 34 80 87
COHIRO
Presentation
Cohiro is a private independent R&D company focused on inflammatory diseases concerning skin, gastrointestinal
and cardiovascular domain. Created in December 2009, Cohiro is a spin-off of LPPCM (Laboratory of Cardio-Metabolic
Pharmacology and Physiopathology Burgundy University Dijon, France). The company provides the following services:
• In vitro and in vivo models for the determination of biological activity and mechanism of action in order to facilitate
the development of drugs, natural extracts, food supplements, healthy food.
• Original in vitro models for ischemia reperfusion to study anti-inflammatory agents acting on acute and chronic
inflammatory diseases and wound healing.
• Specific know-how on the relation between free radicals and the control of inflammatory process.
• Non-invasive imaging techniques are available in rodents to study the cardiac function during chronic inflammation.
• Consulting activities (market opportunities, research development and marketing strategy, team building).
Cohiro works its own product portfolio focused on food supplements and healthy food.
Main sector
Biotechnology.
Subsector
R&D in pharmacy OTC cosmetic and health food.
Primary therapeutic area(s) :
Acute and chronic inflammatory diseases (cardiovascular, skin, GI tract, CNS).
Partnering strategy / collaborations
Cohiro is looking for clients (fee-for-service activities) and partners (development and co-development of new products).
Scientific collaborations are also considered for European research programs (FP7 and other...).
Client portfolio
Biophytis, BIVB (Bureau for Burgundy Wine), Burgundy University, INRA Dijon France (Institute for Agronomic Research),
INSERM U466 France (Institute for Medical Research), Naturex, Phyticforme, Pileje, SEB, TroisBulbes, Urgo.
Address
UFR de Médecine de Dijon
7 Boulevard Jeanne d’Arc, BP 87900 - 21079 DIJON CEDEX - FRANCE
http://www.cohiro.fr
Contact
Dr. Patrick Dutartre, CEO
+33 (0)3 80 39 32 76
[email protected]
Engicare
Presentation
Engicare® is a novel and integrated platform providing its clients with a wide-range of advanced customized research
services, from protein conception to biological validation. Engicare®’s goal is to become a leading partner in the field of
recombinant proteins.
Engicare® combines robust and mature biomanufacturing processes with innovative technologies such as in vivo imaging
and proposes the following services:
• Protein engineering: from conception of a new molecule to the integration of DNA in customized expression vectors
• Biomanufacturing: up to 30L, transient and stable production, batch and fed-batch optimization
• Biological validation: cell-based assays, in vivo biodistribution studies
• Efficacy studies: wide-range of endpoints in models of oncology / cardio-metabolic diseases
• Companion imaging biomarkers: customized elaboration and testing
This complementary and unique approach will facilitate and accelerate the development of your protein-based products in
the rapidly growing market of genetically-engineered proteins.
Main sector
Biotechnology / R&D services
Subsector
Cell culture / CMO / CRO / Diagnostic services / Drug delivery / Screening / Synthesis services
Primary therapeutic area(s) :
Cardiovascular
Endocrine / nutritional and metabolic diseases
Neoplasms / cancer / oncology
Partnering strategy / collaborations
New customers and partners
Strategic collaborations, recombinant proteins development
Client portfolio
Mid size and big pharma/biotech companies
Address
Engicare - NVH Medicinal
57, rue Vannerie - 21000 Dijon cedex - FRANCE
Contact
[email protected] (PhD, Head of Engicare platform)
[email protected] (PhD, Project manager)
ICTA
Presentation
CRO - Full Service in Clinical trial for APIs, Vaccines, Cell/Gene Therapies, Medical Devices and Diagnostics
Main sector
Human Clinical Research
Subsector
All Human Therapeutic indications
Primary therapeutic area(s) :
Oncology / Cardiology / CNS / Metabolism / Infection…
Partnering strategy / collaborations
Long Term Strategic Partners in Eastern Europe/North America/Asia
Client portfolio
Top 20 Pharmas, Mid-size, Biotechs, Medtechs, Academic institutions
Address
• 11 rue du Bocage, 21121 Fontaine les Dijon - FRANCE
• Lebacher Strasse 4, 66113 Saarbrücken - GERMANY
Contact
Dr Olivier HUMBEY (Head of Business development)
[email protected]
PHARMIMAGE
Presentation
Pharmimage is a public-private strong partnership located in Dijon, Burgundy. A comprehensive set of competences and a
global range of imaging modalities are available among the partners.
Pharmimage is dedicated to answer questions about compounds’ efficiency.
Main sector
Translational pharmacology through imaging.
Subsector
Preclinical and clinical imaging modalities.
Primary therapeutic area(s) :
Oncology, cardiology, infectious diseases.
Partnering strategy / collaborations
University of Burgundy.
Cyclopharma Lab. (cyclotron and radiochemistry platform).
Client portfolio
Pharma / biotech
Academic laboratories
Imaging industry
Address
Pharm’image - 64 rue Sully - 21000 DIJON - FRANCE
Contact
Christophe Deteix, managing director
[email protected]
+33 (0)3 80 39 26 50 - +33 (0)6 32 03 61 87
VIVEXIA
Presentation
CRO specialized in the evaluation of the efficacy of anti-infectious drug candidates – human-like pharmacodynamics – in
vivo infectious diseases models
Main sector
Preclinical Research – Biotechnology / R&D Services
Subsector
Contract Research Organization - Antibiotherapy
Primary therapeutic area(s) :
Infectious Diseases (bacterial/fungal/viral) – Nosocomial infections
Pharmacodynamic – Bacterial resistance – Evaluation of new therapeutic options
Partnering strategy / collaborations
Partners developing new antibacterial/antifungal molecules
Partners seeking for developing new relevant models of in vivo infection
Client portfolio
Big Pharmas, Mid-size, Biotechs, Medtechs, Academic institutions
Address
• 8 Boulevard Maréchal de Lattre de Tassigny 21000 Dijon - France (Lab)
• 2 rue Jean Philippe Rameau 21120 Gemeaux - France (Headquarters)
Contact
Dr Delphine Croisier-Bertin (CEO)
[email protected]
WELIENCE - ICMUB
Presentation
The program “TIMBIOKEM- Chemistry for Molecular Imaging”, set up by Welience (Business unit of the University of
Burgundy), aims to serve and assist academic laboratories and private companies by providing customized bioconjugation
services. In particular, TIMBIOKEM can give access to imaging tools for target validation, monitoring of drug distribution and
pharmacokinetics/pharmacodynamics studies. Thanks to our well established expertise in chelation chemistry, fluorescent
probes and peptide synthesis, we can prepare customized targeted-probes, such as fluorescent, radiolabeled or dual-labeled
molecules. We can also apply our technology to develop imaging agents, imaging biomarkers or theranostic systems.
Main sector
Biotechnologie-R&D services/Chemistry
Subsector
Synthesis services – CRO
Primary therapeutic area(s) :
Cancer/Oncology
Diseases of the nervous system
Partnering strategy / collaborations
We are looking for partners interested in using in vivo preclinical imaging to develop therapeutic antibodies or tumortargeting peptides. We are also interested in collaborations with Biotech companies and research organizations that are
looking for the development of specific imaging agents, companion biomarkers.
Client portfolio
The laboratory has worked successfully with several academic groups and partners to prepare novel radioimmunoconjugates, nanoparticles decorated with radiometal chelators or peptides conjugates.
Address
Institut de Chimie Moléculaire de l’Université de Bourgogne
9, avenue Alain Savary – 21000 DIJON - FRANCE
Contact
Dr. Claire BERNHARD
Project Manager
[email protected]